BioPharmSignal logoBioPharmSignal

Biotech News

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

Cellectis (CLLS)CellectisCompany update

New York, NY - May 20, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/

Related news

CLLSCellectis2026-08-06 20:30 EST

Cellectis Reports Financial Results for the Second Quarter 2026

CLLSCellectis2026-06-25 20:30 EST

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

ARGXArgenx2026-08-03 20:01 EST

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

REPLReplimune Group2026-07-30 22:15 EST

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

View all latest news

Cellectis

Gene-Edited Allogeneic Cell Therapy Cellectis develops off-the-shelf CAR T-cell therapies using TALEN gene editing and related genome-engineering technologies. UCART Platform The platform modifies healthy donor T cells to add tumor targeting and reduce immune incompatibility, enabling standardized inventory-based treatment. BALLI-01 The...

Recent company news

CLLSCellectis2026-08-06 20:30 EST

Cellectis Reports Financial Results for the Second Quarter 2026

CLLSCellectis2026-07-30 20:30 EST

Cellectis to Report Second Quarter Financial Results on August 6, 2026

CLLSCellectis2026-06-25 20:30 EST

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

CLLSCellectis2026-06-11 06:40 EST

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

CLLSCellectis2026-06-09 20:30 EST

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Stock data

Close
3.41 USD
Market cap
340.07M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States